Hybrid chemotherapy regimen (FLAG-IDA-vincristine-prednisone) for acute leukemia with mixed-phenotype blasts
| Autor: | Patrick W. Burke, Lydia L. Benitez, Anthony J. Perissinotti, Justin H Reid, Bernard L. Marini, Winston Y Lee, Kristen Pettit, Daniel F. Boyer, Dale L. Bixby |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Vincristine Disease-Free Survival 03 medical and health sciences 0302 clinical medicine Internal medicine Antineoplastic Combined Chemotherapy Protocols Granulocyte Colony-Stimulating Factor medicine Idarubicin Humans Aged Retrospective Studies Acute leukemia business.industry Standard treatment Cytarabine Hematology Middle Aged medicine.disease Chemotherapy regimen Survival Rate Leukemia Regimen Leukemia Myeloid Acute Oncology 030220 oncology & carcinogenesis FLAG (chemotherapy) Prednisone Female business Vidarabine 030215 immunology medicine.drug |
| Zdroj: | Leukemia research. 103 |
| ISSN: | 1873-5835 |
| Popis: | Background Acute leukemia with mixed-phenotype blasts is associated with poor outcomes. There are no standard treatment regimens. Due to disease heterogeneity, controversy exists over whether an AML-based, ALL-based, or a combined (hybrid) AML/ALL-based regimen is most appropriate. Materials and Methods We conducted a single-center, retrospective case series review of patients with acute leukemia with mixed phenotype blasts as described by the European Group for Immunological Characterization of Leukemia (EGIL) or the 2008 WHO classification. Patients were treated from November 2014 and December 2019 with the combination chemotherapy regimen FLAG-idarubicin-vincristine-prednisone with or without rituximab. Outcomes included induction response, time to transplant, time to relapse, overall survival, time to neutrophil or platelet recovery, infection, and duration of hospitalization. Results The median age was 68 years (range 21−77). Six patients (87.5 %) had unfavorable/complex cytogenetics. All patients achieved a complete remission (CR) or complete remission with incomplete hematologic recovery (CRi). Estimated 1-year overall survival was 85.7 %. There were no deaths during induction, with a 22 day median duration of hospitalization for induction. Conclusion The combination of FLAG, idarubicin, vincristine, and prednisone (FLAG-VIPR) demonstrated favorable induction responses in a disease state with historically poor outcomes and should be studied in a prospective clinical trial. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect